Lilly Comments on Court Ruling in Amylin Litigation

INDIANAPOLIS, May 25, 2011 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY)
today commented on a ruling issued by the U.S. District Court for the Southern
District of California granting a request by Amylin Pharmaceuticals for a
temporary restraining order (TRO) related to litigation involving the two
companies’ diabetes collaboration agreement.

“We are disappointed with the Court’s decision to grant a temporary restraining
order in this case,” said Robert A. Armitage, senior vice president and general
counsel for Lilly. “We have complied with our contractual obligations under our
agreements with Amylin in a manner fully consistent with all applicable laws. We
believe that Amylin’s allegations against Lilly are entirely without merit and
we fully expect to prevail in this litigation.”

Enrique Conterno, president of Lilly Diabetes, said, “The focus of our business
remains on the patients we serve. We seek to offer a broad range of treatment
options, including important new therapies, to people with diabetes and their
health care providers.”

Lilly is taking the appropriate steps to comply with the Court’s order,
including as it relates to the activities of its sales force, while working to
mitigate the impact of any temporary modifications to its diabetes business.

Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -
through medicines and information – for some of the world’s most urgent medical
needs. Additional information about Lilly is available at www.lilly.com. C-LLY

This press release contains forward-looking statements about our alliance with
Amylin, and it reflects Lilly’s current beliefs. There are substantial risks and
uncertainties in the process of drug development and commercialization. Further,
we cannot predict the outcome of any litigation with Amylin or its effect on our
collaboration. For further discussion of risks and uncertainties, please see
Lilly’s latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange
Commission. Lilly undertakes no duty to update forward-looking statements.

SOURCE Eli Lilly and Company